Close Menu

MilliporeSigma

The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.

Promega said it plans to use the technology to create new research products for investigating endogenous biology.

As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.

The Broad will now offer licenses for both its own CRISPR IP and MilliporeSigma's to companies using CRISPR in their research and development activities.

The firms originally inked the agreement in 2015 and have now extended it until 2025.

The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.  

The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.

Universities and research institutes are making CRISPR/Cas9 more accessible than ever through new and existing core facilities.

Sales for the firm's life science segment jumped 25 percent year over year to €3.36 billion from €2.68 billion.

After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.